Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452085 | 1.00 | HTR2A (0.49) | HTR2ATAAR1HTR2C | |
| SCHEMBL30467763 | 0.86 | HTR2A (0.47) | HTR2ATAAR1HTR2C | |
| SCHEMBL24252762 | 0.86 | HTR2A (0.47) | HTR2ATAAR1HTR2C | |
| SCHEMBL29733616 | 0.84 | HTR2A (0.68) | HTR2ATAAR1HTR2C | |
| SCHEMBL1145570 | 0.84 | HTR2A (0.68) | HTR2ATAAR1HTR2C | |
| SCHEMBL3220881 | 0.79 | PDE4A (0.46) | HTR2ATAAR1HTR2C | |
| SCHEMBL30451569 | 0.79 | HTR2A (0.47) | HTR2ATAAR1HTR2C | |
| SCHEMBL24252452 | 0.79 | HTR2A (0.47) | HTR2ATAAR1HTR2C | |
| SCHEMBL7165538 | 0.78 | SMN1; SMN2 (0.53) | HTR2ATAAR1HTR2C | |
| SCHEMBL31063345 | 0.76 | HTR2A (0.54) | HTR2ATAAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | HTR2A 2891/4885TAAR1 3883/4885HTR2C 3873/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | HTR2A 2891/4885TAAR1 3883/4885HTR2C 3873/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | HTR2A 2891/4885TAAR1 3883/4885HTR2C 3873/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | HTR2A 895/4885TAAR1 914/4885HTR2C 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.